Screener / SEC EDGAR /CIK 0001651308 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

BeOne Medicines Ltd. ONC

Compare with peers Embed
SEC comment letters, last 20 years

7 reviews of ONC's filings by SEC staff

UPLOAD and CORRESP
Reviews 7 latest letter Jun 2, 2025
Questions asked 34 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 12 UPLOAD
  2. 2. Questions in them 34 numbered comments
  3. 3. Company replies 13 CORRESP
  4. 4. Reviews closed 6 of 7 closing letter

Half the closed reviews took 70 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2024

2025-06-02 to 2025-06-18 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2025-06-18
RevenueChina
Form 10-K for Fiscal Year Ended December 31, 2024 · Notes to the Consolidated Financial Statements
SEC asked
Collaborative and Licensing Arrangements, page 151 1. You disclose that other collaboration revenue consists primarily of revenue under the Novartis broad markets agreement and, beginning in 2024, royalty revenue under the Amgen collaboration agreement. Please revise your future filings to clarify the products to which the Amgen royalty revenue relates.
Rest of the question

In this regard, your disclosure on page 153 indicates that beginning in October 2019 you were responsible for the commercialization of XGEVA, KYPROLIS and BLINCYTO in China for a period of five to seven years, and that following the commercialization period you have the right to retain one product and receive royalties on sales in China for an additional five years on the products not retained. Clarify whether the commercialization period has ended for any of these products and if not, to which products the royalty revenue relates.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure contained in future relevant filings with the Commission, with necessary updates.

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact Edwin O’Connor of Goodwin Procter LLP at [email protected] or (212) 813-8853.
Read in the reply

Also in this review: closing letter, 2025-06-18

Form S-4

2024-09-03 to 2025-03-06 · 3 questions · 3 letters from the SEC, 4 from the company
No closing letter
Risk factorsChina
Cover Page
SEC asked
We note that you have an indirect controlling interest in your subsidiaries organized under the laws of the People’s Republic of China through BeiGene (Hong Kong) Co., Limited. Please revise this registration statement to provide specific and prominent disclosures in the prospectus cover page about the legal and operational risks associated with Chinabased companies, or otherwise advise.
Rest of the question

For additional guidance, please see the Division of Corporation Finance's Sample Letters to China-Based Companies issued by the Staff in December 2021 and July 2023. Risk Factors, page 12 We note that you are incorporating by reference risk factors disclosed in your Form 10-K for the fiscal year ended December 31, 2023 and subsequent reports on Form 10-Q. We 2. also note the changes you made to the disclosure appearing in the Risk Factor section of the Form 10-K relating to legal and operational risks associated with operating in China and PRC regulations as compared to your previously reviewed 10-K completed on June 15, 2022, warranting revised disclosure to mitigate the challenges you face and related disclosures. The Sample Letters to China-Based Companies seeks specific disclosure relating to the risk that the PRC government may intervene in or influence your operations at any time, or may exert control over operations of your business, which could result in a material change in your operations and/or the value of the securities. We remind you that, pursuant to federal securities rules, the term “control” (including the terms “controlling,” “controlled by,” and “under common control with”) as defined in Securities Act Rule 405 means “the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract, or otherwise.” We do not believe that your revised disclosure conveys the same risk. Please amend this Form S-4 to restore your disclosures in these areas to the disclosures as they existed in prior filings, or otherwise advise. As examples, and without limitation, we note that your disclosure in your Annual Report on Form 10-K does not contain disclosure (i) that the PRC government may intervene in or influence your operations at any time with little or no advance notice; (ii) references that the Chinese government may intervene, influence, or control your business or value of your securities; and that (iii) the Chinese government indicated an intent to exert more oversight and control over offerings that are conducted overseas.

ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Registration Statement has been amended to provide specific and prominent disclosures on the prospectus cover page about the legal and operational risks associated with China-based companies.
Read in the reply
Risk Factors
SEC asked
We note your response to prior comment 2 as reflected in the Current Report on Form 8-K that was filed on September 30, 2024. In particular, we note in the summary of risk factors you discuss risks arising from the legal system in China, including risks and uncertainties regarding the enforcement of laws. Please also include that the rules and regulations in China can change quickly and with little advance notice.
Rest of the question

In addition, given the Chinese government’s significant oversight and discretion over the conduct and operations of your business, please revise your risk factors to describe any material impact that intervention, influence, or control by the Chinese government has or may have on your business or on the value of your securities. Specifically, 1. please highlight the risk that the Chinese government may intervene or influence your operations at any time, which could result in a material change in your operations and/or the value of your securities. Further, in the risk factor summary, please include the risk that the Chinese government may intervene or influence your operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in your operations and/or the value of your securities. For additional guidance, please see the Division of Corporation Finance's Sample Letters to China-Based Companies issued by the Staff in December 2021 and July 2023.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise the amended and restated risk factors contained in the Current Report on Form 8-K filed by the Company on September 30, 2024 to provide additional disclosures responsive to the Staff’s comment, as follows:

Summary of Risk Factors

[…]

•The PRC government may intervene or influence our operations at any time, and has the ability to exert significant oversight and control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, which could
Rest of the answer

result in a material change in our operations and, as a result, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless.

•There are uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, and rules and regulations in China can change quickly with little advance notice.

*The PRC government may intervene or influence our operations at any time, and has the ability to exert significant oversight and control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and, as a result, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless.

The Chinese government may intervene or influence our operations at any time, or may exert control over operations of our business, which could result in a material change in our operations and/or the value of our securities. Any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.

For example, the PRC government has indicated its intent to exert more oversight and control over securities offerings and other capital markets activities that are conducted overseas and foreign investment in China-based companies. If the PRC authorities attempt to exercise such control or influence through regulation over our PRC subsidiaries, we could be required to restructure our operations to comply with such regulations or potentially cease operations in the PRC entirely, which could adversely affect our business, results of operations and financial condition. Any such action, once taken by the PRC government, could result in a material change in our operations, and could also significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless.

Additionally, For example, the PRC government initiated a series of regulatory actions and statements to regulate business operations in China, including cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed overseas using the variable interest entity (“VIE”) structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. For example, in July 2021, the relevant PRC government authorities made public the Securities Opinions, which emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies and proposed to take effective measures, such as promoting the construction of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas listed companies.

Furthermore, in July 2021, the PRC government provided guidance on China-based companies raising capital outside of China, including through VIE structures. In light of such developments, the SEC has imposed enhanced disclosure requirements on China-based companies seeking to register securities with the SEC. In February 2023, the CSRC released the Overseas Listing Trial Measures and five relevant guidelines which became effective as of March 31, 2023. According to the Overseas Listing Trial Measures, where Chinese companies that have directly or indirectly listed securities in overseas markets conduct follow-on offering of equity securities in such overseas markets, they shall fulfill the filing procedures with and report relevant information to the CSRC. As the Overseas Listing Trial Measures are subject to changes and may continue to evolve, we cannot assure you that we would not be deemed as an indirect overseas listed Chinese company under the Overseas Listing Trial Measures. If we are deemed as an indirect overseas listed Chinese company but fail to complete the filing procedures with the CSRC for any of our follow-on offerings or follow relevant reporting requirements thereunder, we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council. See also the section of our Annual Report titled “Part I—Item 1—Business—Government Regulation—PRC Regulation—Regulations Relating to Overseas Listing”. We are currently evaluating the implications and potential impact of the Overseas Listing Trial Measures and will continue to closely monitor the interpretation and implementation of the Overseas Listing Trial Measures. Due to our operations in China and stock listings in and outside of China, the Overseas Listing Trial Measures and any future PRC, U.S. or other rules and regulations that place restrictions on capital raising could adversely affect our business and results of operations and could significantly limit or completely hinder our ability to offer or continue to offer our ADSs or ordinary shares to investors, and could cause the value of our ADSs or ordinary shares to significantly decline or become worthless.

In February 2023, the CSRC and other PRC governmental authorities jointly issued the revised Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies (the “Revised Confidentiality Provisions”), which became effective as of March 31, 2023. According to the Revised Confidentiality Provisions, Chinese companies that directly or indirectly conduct overseas offerings and listings, shall strictly abide by the laws and regulations on confidentiality when providing or publicly disclosing, either directly or through their overseas listed entities, materials to securities services providers. In the event such materials contain state secrets or working secrets of government agencies, the Chinese companies shall first obtain approval from authorities, and file with the secrecy administrative department at the same level with the approving authority; in the event that such materials, if divulged, will jeopardize national security or public interest, the Chinese companies shall comply with procedures stipulated by national regulations. The Chinese companies shall also provide a written statement of the specific sensitive information provided when providing materials to securities service providers, and such written statements shall be retained for inspection. The interpretation and implementation of the Revised Confidentiality Provisions may continue to evolve.

Currently, these statements and regulatory actions have had no impact on our daily business operations or our ability to accept foreign investments and list our securities on a U.S. or other foreign exchange. However, it is highly uncertain how the legislative or administrative agencies will further interpret, modify or implement such laws and regulations, or if they will promulgate any new laws or regulations, and their potential impact on our daily business operations, the ability to accept foreign investments and list our securities on a U.S., Hong Kong, or other stock exchanges. There are still substantial uncertainties as to how PRC governmental authorities will regulate overseas listing in practice and whether we are required to obtain any specific regulatory approvals from PRC governmental authorities for our offshore offerings. If PRC regulatory agencies later promulgate new rules or explanations requiring that we obtain their approvals for our future offshore offerings, we may be unable to obtain such approvals in a timely manner, or at all, and such approvals may be rescinded even if obtained. Any such circumstance could significantly limit or completely hinder our ability to continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. In addition, implementation of industry-wide regulations directly targeting our operations could cause the value of our securities to significantly decline. Therefore, investors of our company face potential uncertainty from actions taken by the government authorities affecting our business. Any intervention by the PRC government in our operations could undermine our business plan and cause the value of an investment in the Company to significantly decline or become worthless.

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact Edwin O’Connor of Goodwin Procter LLP at [email protected] or (212) 813-8853.

Read in the reply
Cover Page
SEC asked
We note your response to prior comment 1 and your disclosure about the legal and operational risks associated with being based in or having the majority of the company’s operations in China. Please also disclose that these risks could result in a material change in your operations as you do in your incorporated by reference risk factors found in Item 1A of Part II of the Company’s Quarterly Report on Form 10-Q for
Rest of the question

the quarter ended September 30, 2024. Further, in your description of how cash is transferred through your organization please also provide a cross-reference to the consolidated financial statements.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the cover page of Amendment No. 2 to the Registration Statement on Form S-4 has been revised as requested by the Staff.

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact Edwin O’Connor of Goodwin Procter LLP at [email protected] or (212) 813-8853.
Read in the reply

Also in this review: company letter, Mar 6, 2025

Form 10-K for the Fiscal Year Ended December 31, 2023

2024-07-25 to 2024-09-05 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2024-09-05
Risk factorsChina
General
SEC asked
We note the changes you made to your disclosure appearing in Item 1. Business and Item 1A. Risk Factor sections relating to legal and operational risks associated with operating in China and PRC regulations. It is unclear to us that there have been changes in the regulatory environment in the PRC since the prior 10-K review completed on June 15, 2022, warranting revised disclosure to mitigate the challenges you face
Rest of the question

and related disclosures. The Sample Letters to China-Based Companies sought specific disclosure relating to the risk that the PRC government may intervene in or influence your operations at any time, or may exert control over operations of your business, which could result in a material change in your operations and/or the value of the securities you are registering for sale. We remind you that, pursuant to federal securities rules, the term “control” (including the terms “controlling,” “controlled by,” and “under common control with”) as defined in Securities Act Rule 405 means “the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract, or otherwise.” We do not believe that your revised disclosure conveys the same risk. In future filings, please restore your disclosures in these areas to the disclosures as they existed in prior filings. As examples, and without limitation, we note that your disclosure in your Annual Report on Form 10-K does not contain disclosure (i) that the PRC government may intervene in or influence your operations at any time with little or no advance notice; (ii) references that the Chinese government may intervene, influence, or control your business or value of your securities; and that (iii) the Chinese government indicated an intent to exert more oversight and control over offerings that are conducted overseas.

ONC answered
The Company respectfully acknowledges the Staff’s comment. As the Company continues to expand globally, the Company believes that it was appropriate to update its disclosures to reflect this growth and the resulting changes in its risk profile. However, the Company acknowledges that there have not been significant changes in the regulatory environment in the PRC since the prior 10-K review completed by the Staff, and therefore agrees to restore the disclosures contained in Item I. Business and Item IA.
Rest of the answer

Risk Factor sections, which relate to legal and operations risks associated with operating in China and PRC regulations as they previously existed in the Company’s annual report on Form 10-K for the year ending December 31, 2022 in its future relevant Exchange Act periodic reports, with necessary updates.

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact Edwin O’Connor at [email protected] or (212) 813-8853.

Read in the reply
In its next report

First report after the company's reply of Aug 21, 2024: 10-Q filed Nov 12, 2024 ↗, against the 10-Q filed May 8, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Jul 31, 2024, closing letter, 2024-09-05

Form 10-K for the Fiscal Year Ended December 31, 2022

2023-07-21 to 2023-12-07 · 6 questions · 2 letters from the SEC, 2 from the company
Review closed 2023-12-07
China
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections, page 135
SEC asked (1)
We note your statement that as of the date of this Annual Report, no governmental entity in mainland China or Hong Kong has filed a Schedule 13D or 13G, there are no material contracts with such foreign governmental party, and there is no such foreign governmental representative on your Board in connection with your required submission under paragraph (a).
Rest of the question

Please supplementally describe any materials that were reviewed and tell us whether you relied upon any legal opinions or third party certifications such as affidavits as the basis for your submission. In your response, please provide a similarly detailed discussion of the materials reviewed and legal opinions or third party certifications relied upon in connection with the required disclosures under paragraphs (b)(2) and (3).

ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that in order to make the statements in Item 9C of its 2022 Annual Report pursuant to Item 9C, paragraph (a), (b)(2) and (b)(3) of Form 10-K, the Company reviewed the following materials:

•The Schedule 13D and/or 13G EDGAR filings made by beneficial owners of the Company (the “EDGAR Filings”); and

•The Company’s material contracts.

The Company respectfully advises the Staff that it did not receive or rely upon any legal opinions or third party certifications for its assessments as it relates to the disclosure
Rest of the answer

under Item 9C of its 2022 Annual Report pursuant to Item 9C, paragraphs (a), (b)(2) and (b)(3). However, prior to submitting this response letter to the Staff, the Company collected certifications from each member of the board of directors of the Company (the “Board”) and each member of the boards of its consolidated foreign operating entities confirming he or she is not currently, nor has ever been, an official of the Chinese Communist Party (the “Certificate”).

The Company respectfully advises the Staff that it intends to collect the Certificate from each member of the Board of the Company and each member of the boards of its consolidated foreign operating entities, as applicable, on an annual basis hereafter in connection with the director questionnaire process to the extent the Company is identified by the Commission pursuant to Section 104(i)(2)(A) of the Sarbanes-Oxley Act of 2002 as having retained, for the preparation of the audit report on its financial statements included in the Form 10-K, a registered public accounting firm that has a branch or office that is located in a foreign jurisdiction and that the Public Company Accounting Oversight Board has determined it is unable to inspect or investigate completely because of a position taken by an authority in the foreign jurisdiction (a “Commission-Identified Issuer”).

As we noted in our 2022 Annual Report, on March 23, 2022, following a review process carried out by our audit committee, Ernst & Young Hua Ming LLP resigned as our independent registered public accounting firm for the audit of our financial statements and internal control over financial reporting to be filed with the Commission. On the same day, our audit committee approved the engagement of Ernst & Young LLP, located in Boston, Massachusetts, United States, as the Company’s independent registered public accounting firm for the audit of our financial statements and internal control over financial reporting for the fiscal year ending December 31, 2022. Given that Ernst & Young LLP (United States) now serves as the principal accountant to audit our consolidated financial statements, we expect to be able to comply with the HFCAA and AHFCAA and certify that we have retained a registered public accounting firm that the PCAOB has determined it is able to inspect or investigate which would preclude a further finding by the Commission that we are a Commission-Identified Issuer.

Read in the reply
In its next report

First report after the company's reply of Aug 21, 2023: 10-Q filed Nov 9, 2023 ↗, against the 10-Q filed May 4, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections, page 135
SEC asked (2)
In order to clarify the scope of your review, please supplementally describe the steps you have taken to confirm that none of the members of your board or the boards of your consolidated foreign operating entities are officials of the Chinese Communist Party.
Rest of the question

For instance, please tell us how the board members’ current or prior memberships on, or affiliations with, committees of the Chinese Communist Party factored into your determination. In addition, please tell us whether you have relied upon third party certifications such as affidavits as the basis for your disclosure.

ONC answered
The Company respectfully advises the Staff that in connection with its preparation of the disclosure under Item 9C of the 2022 Annual Report, it gathered and reviewed annual questionnaires (the “2022 Director Questionnaires”) completed by each member of the Board in connection with the 2022 Annual Report and the Company’s Definitive Proxy Statement on Schedule 14A filed on April 27, 2023.
Rest of the answer

Each member of the Board signed a 2022 Director Questionnaire, attesting to the truthfulness and completeness of the responses in his or her 2022 Director Questionnaire, and none of the members of the Board disclosed that they were an official of the Chinese Communist Party.

As noted above, prior to submitting this response letter to the Staff, the Company collected the Certificate from each member of the Board of the Company and each member of the boards of its consolidated foreign operating entities. The Company respectfully advises the Staff that it intends to collect the Certificate from each member of the Board of the Company and each member of the boards of its consolidated foreign operating entities, as applicable, on an annual basis hereafter in connection with the director questionnaire process to the extent the Company is a Commission-Identified Issuer.

Read in the reply
In its next report

First report after the company's reply of Aug 21, 2023: 10-Q filed Nov 9, 2023 ↗, against the 10-Q filed May 4, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections, page 135
SEC asked (3)
We note that your disclosures pursuant to Item 9C(b) refer to either “the Company” or “the Company or its operating subsidiaries.” It is unclear from the context of these disclosures whether “the Company” is meant to encompass you and all of your consolidated foreign operating entities or whether in some instances this term refers solely to BeiGene, Ltd.
Rest of the question

Please note that Item 9C(b) requires that you provide each disclosure for yourself and your consolidated foreign operating entities, including variable interest entities or similar structures. To clarify this matter, please provide the information required by each subsection of Item 9C(b) for you and all of your consolidated foreign operating entities in your supplemental response.

ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that its disclosure regarding “the Company” under Item 9C of the 2022 Annual Report refers to the Company unless otherwise specifically noted. In this regard, the Company notes that Item 9C(b) of Form 10-K (“Item 9C(b)”) only requires that the registrant provides disclosure for itself and its consolidated foreign operating entity or entities with respect to “any such identified foreign issuer that uses a variable-interest entity or any similar structure that results in additional foreign entities being
Rest of the answer

consolidated in the financial statements…” (emphasis added). Thus, the Company respectfully advises the Staff that the Company does not conduct business through variable interest entities or similar structures. To this end, the Company confirms the following with respect to each subsection of Item 9C(b) of Form 10-K:

(1)The Company’s disclosure in the 2022 Annual Report regarding the Company’s registered public accounting firm for the immediately preceding annual financial statement period is also applicable to the Company’s consolidated foreign operating entities. Ernst & Young LLP, located in Boston, Massachusetts, United States, served as the independent registered public accounting firm for the Company and its consolidated foreign operating entities for the audit of the financial statements and internal control over financial reporting for the fiscal year end December 31, 2022. Given that Ernst & Young LLP (United States) now serves as the principal accountant to audit such consolidated financial statements, the Company expects to comply with the HFCAA and AHFCAA and certify that it has retained a registered public accounting firm that the PCAOB has determined it is able to inspect or investigate which would preclude a further finding by the Commission that the Company is a Commission-Identified Issuer.

(2)To the extent known by the Company, the Company is not aware of and has no reason to believe that any governmental entity in the foreign jurisdiction in which the Company is incorporated or otherwise organized owns shares of any capital stock of record of the Company.

(3)The Company has determined that no governmental entity in China has a controlling financial interest in the Company.

(4)To the extent known by the Company, the Company is not aware of and has no reason to believe that any official of the Chinese Communist Party is a board member of the Company or its consolidated foreign operating subsidiaries. The Company respectfully directs the Staff to the Company’s response to comments #1 and #2 above with regard to the 2022 D&O Questionnaires and Certificates, as applicable.

(5)The articles of incorporation of the Company, as amended, does not contain any wording received from any charter of the Chinese Communist Party.

Read in the reply
In its next report

First report after the company's reply of Aug 21, 2023: 10-Q filed Nov 9, 2023 ↗, against the 10-Q filed May 4, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections, page 135
SEC asked (4)
We note your disclosure provided pursuant to Item 9C(b)(4) that no “officials of the Chinese government” are members of your board or the board(s) of your operating subsidiaries and your additional statement that there is no “foreign government representative” on your board.
Rest of the question

Please confirm, if true, that no members of your board of directors or the boards of your consolidated foreign operating entities are officials of the Chinese Communist Party.

ONC answered
The Company acknowledges the Staff’s comment and confirms that no members of the Board or the boards of the Company’s consolidated foreign operating entities are officials of the Chinese Communist Party. The Company respectfully directs the Staff to the Company’s response to comments #1 and #2 above with regard to the Certificates obtained in connection with this letter and to be obtained from such board members on an annual basis hereafter, as applicable.
Read in the reply
In its next report

First report after the company's reply of Aug 21, 2023: 10-Q filed Nov 9, 2023 ↗, against the 10-Q filed May 4, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections, page 135
SEC asked (5)
With respect to your disclosure pursuant to Item 9C(b)(5), we note that you have included language that such disclosure is “to the extent known by the Company.” Please supplementally confirm without qualification, if true, that your articles and the articles of your consolidated foreign operating entities do not contain wording from any charter of the Chinese Communist Party.
ONC answered
The Company acknowledges the Staff’s comment and confirms that neither the articles of incorporation of the Company, as amended, nor any articles of incorporation for the Company’s consolidated foreign operating entities contain any wording from any charter of the Chinese Communist Party.

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact Edwin O’Connor at [email protected] or (212) 813-8853.
Read in the reply
In its next report

First report after the company's reply of Aug 21, 2023: 10-Q filed Nov 9, 2023 ↗, against the 10-Q filed May 4, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections, page 135
SEC asked
As noted in your response to prior comment 3, Item 16I(b) of Form 20-F states: “Also, any such identified foreign issuer that uses a variable-interest entity or any similar structure [emphasis added] that results in additional foreign entities being consolidated in the financial statements of the registrant is required to provide the below disclosures for itself and its consolidated foreign operating entity or
Rest of the question

entities.” Additionally, page 15 of our Release No. 34-93701, “Holding Foreign Companies Accountable Act Disclosure,” clarifies that a registrant should “look through a VIE or any structure [emphasis added] that results in additional foreign entities being consolidated in the financial statements of the registrant and provide the required disclosures about any consolidated operating company or companies in the relevant jurisdiction.” As previously requested, please provide us with the information required by Items 16I(b)(2) through (b)(5) for all of your consolidated foreign operating entities in your supplemental response.

ONC answered
The Company acknowledges the Staff’s comment and confirms the following with respect to Item 9C(b)(2) through (b)(5) of Form 10-K:

(2)To the extent known by the Company, the Company is not aware of and has no reason to believe that any governmental entity in the foreign jurisdiction in which the Company is incorporated or otherwise organized owns shares of any capital stock of record of the Company.
Rest of the answer

Furthermore, to the extent known by the Company, the Company is not aware of and has no reason to believe that any government entity in the foreign jurisdiction where its consolidated foreign operating entities are incorporated or otherwise organized owns shares of any capital stock of record of its consolidated foreign operating entities.

(3)The Company has determined that no governmental entity in China has a controlling financial interest in the Company or its consolidated foreign operating entities.

(4)To the extent known by the Company, the Company is not aware of and has no reason to believe that any official of the Chinese Communist Party is a board member of the Company or its consolidated foreign operating entities.

(5)The articles of incorporation of the Company, as amended, and those of its consolidated foreign operating entities, do not contain any wording received from any charter of the Chinese Communist Party.

***

If you or any other member of the Staff have any questions with regard to the foregoing response, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact Edwin O’Connor at [email protected] or (212) 813-8853.

Read in the reply
In its next report

First report after the company's reply of Oct 4, 2023: 10-Q filed Nov 9, 2023 ↗, against the 10-Q filed May 4, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Jul 26, 2023, closing letter, 2023-12-07

Form 10-K

2022-04-06 to 2022-06-15 · 12 questions · 2 letters from the SEC, 2 from the company
Review closed 2022-06-15
ChinaRisk factorsLiquidity and cashCybersecurityResults discussion (MD&A)
After reviewing your response to these comments, we may have additional comments. Part I · Item 1. Business, page 5
SEC asked (1)
At the onset of Part I, please disclose prominently that you are not a Chinese operating company but a Cayman Islands holding company with operations conducted by your subsidiaries. In addition, please provide early in the Business section a diagram of your corporate structure.
ONC answered
The Company acknowledges the Staff’s comment and respectively advises the Staff that on page 53 of the 2021 Annual Report, the Company discloses that “[w]e are an exempted company incorporated in the Cayman Islands with limited liability on October 28, 2010. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company.” However, in response to the Staff’s comments, in future annual reports on Form 10-K, the Company will disclose, at the onset of Part I, that it is not a Chinese operating
Rest of the answer

company but a Cayman Islands holding company with operations conducted by its subsidiaries. The Company will also provide early in the Business section a diagram of its corporate structure. In this regard, please refer to Appendix A for a diagram of the Company’s corporate structure that will be provided in future annual reports on Form 10-K.

Additionally, the Company undertakes to update, at the onset of Part I Business section, in its future annual reports on Form 10-K as follows, with necessary updates:

“Our Holding Company Structure

We are a holding company incorporated in the Cayman Islands with operations primarily conducted through our subsidiaries in the United States, China, United Kingdom, Switzerland and Australia. The following diagram depicts a summary of our corporate structure. Currently, our corporate structure contains no variable interest entities.”

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

After reviewing your response to these comments, we may have additional comments. Part I · Item 1. Business, page 5
SEC asked (2)
We note your disclosure beginning on page 94 regarding "Risks Related to Our Doing Business in the PRC." Please provide a more prominent disclosure about the legal and operational risks associated with being based in or having the majority of the company’s operations in China.
Rest of the question

Your disclosure should make clear whether these risks could result in a material change in your operations and/or the value of your securities or could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. Your disclosure should address how recent statements and regulatory actions by China’s government, such as those related to data security or anti-monopoly concerns, have or may impact the company’s ability to conduct its business, accept foreign investments, or list on a U.S. or other foreign exchange.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in future relevant Exchange Act periodic reports to address the legal and operational risks of operating in China, the potential effects of such matters on our operations and/or value of our securities, and recent statements and regulatory actions by China’s government and their effect on the Company.
Rest of the answer

Please refer to Appendix C for the risk factors the Company will include in future relevant Exchange Act periodic reports.

The Company undertakes to update the Business section in future annual reports on Form 10-K as follows, with necessary updates:

“Doing Business in the PRC

As a result of our operations in the PRC, the PRC government may intervene in or exert influence over our operations at any time with little or no advanced notice, which could result in a material change in our operations and/or the value of our ADSs, ordinary shares, or RMB Shares. For example, the PRC government has recently published new policies that significantly affected certain industries such as the education and internet industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding any industry that could adversely affect the business, financial condition and results of operations of our company.

Furthermore, the PRC government has also recently indicated an intent to exert more oversight and control over securities offerings and other capital markets activities that are conducted outside of China and over foreign investment in China-based companies. Any such action, once taken by the PRC government, could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless. Recently, the PRC government initiated a series of regulatory actions and statements to regulate business operations in China with little advance notice, including enforcement actions against illegal activities in the securities market, enhancing supervision over China-based companies listed outside of China using the variable interest entity structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. For example, on July 6, 2021, the relevant PRC government authorities made public the Opinions on Intensifying Crack-Down on Illegal Securities Activities. These opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies and proposed to take measures, such as promoting the construction of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. On November 14, 2021, the Cyberspace Administration of China (the “CAC”) released the draft Administrative Regulations on Cyber Data Security (the “Draft Cyber Data Security Regulations”) for public comments, which requires, among others, that a prior cybersecurity review should be required for listing abroad of data processors which process over one million users’ personal information, and the listing of data processors in Hong Kong which affects or may affect national security.

The Chinese government may further promulgate relevant laws, rules and regulations that may impose additional and significant obligations and liabilities on overseas listed PRC companies regarding data security, cross-border data flow, anti-monopoly and unfair competition, and compliance with China’s securities laws. It is uncertain whether or how these new laws, rules and regulations and the interpretation and implementation thereof may affect us, but among other things, our ability to obtain external financing through the issuance of equity securities in the United States, Hong Kong or other markets could be negatively affected, and as a result, the trading prices of our ADSs, ordinary shares and RMB Shares could significantly decline or become worthless. For a detailed description of risks related to our doing business in China, see “Item 1A. Risk Factors—Risks Related to Our Doing Business in the PRC.””

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

After reviewing your response to these comments, we may have additional comments. Part I · Item 1. Business, page 5
SEC asked (3)
We note your discussion of PCAOB inspections beginning on page 95. Please prominently disclose whether your auditor is subject to the determinations announced by the PCAOB on December 16, 2021 and whether and how the Holding Foreign Companies Accountable Act and related regulations will affect your company, including disclosing that you were identified by the Commission under the HFCAA.
Rest of the question

In addition, disclose that trading in your securities may be prohibited under the Holding Foreign Companies Accountable Act if the PCAOB determines that it cannot inspect or investigate completely your auditor, and that as a result an exchange may determine to delist your securities.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in the Business section of future annual reports on Form 10-K to prominently disclose that its previous auditor is subject to the determinations announced by the PCAOB on December 16, 2021, including that the Company was identified by the Commission under the Holding Foreign Companies Accountable Act and related regulations.
Rest of the answer

The Company also advises the Staff that it will include new risk factor disclosures in the next quarterly report on Form 10-Q that will be filed on May 9, 2022, which discusses the related risks. Please refer to Appendix D for the risk factors the Company will include in the next quarterly report on Form 10-Q.

The Company undertakes to update the Business section in future annual reports on Form 10-K as follows, with necessary updates:

“Status under Holding Foreign Companies Accountable Act

On December 2, 2021, the U.S. Securities and Exchange Commission (“SEC”) adopted rules (the “Final Rules”) to implement the Holding Foreign Companies Accountable Act (the “HFCAA”), which became law on December 18, 2020. The HFCAA includes requirements for the SEC to identify issuers who file annual reports with audit reports issued by independent registered public accounting firms located in foreign jurisdictions that the Public Company Accounting Oversight Board (“PCAOB”) is unable to inspect or investigate completely because of a position taken by a non-U.S. authority in the accounting firm’s jurisdiction (“Commission-Identified Issuers”). The HFCAA also requires that, to the extent that the PCAOB has been unable to inspect an issuer’s independent registered public accounting firm for three consecutive years since 2021, the SEC shall prohibit the issuer’s securities registered in the United States from being traded on any national securities exchange or over-the-counter markets in the United States.

Under the Final Rules, the SEC adopted submission and disclosure requirements by amending Form 10-K and other annual reporting forms and established procedures to identify issuers and prohibit the trading of the securities of certain registrants as required by the HFCAA. Specifically, the Final Rules require each Commission-Identified Issuer to submit documentation to the SEC annually on or before its annual report due date that establishes that it is not owned or controlled by a government entity in its public accounting firm’s foreign jurisdiction and require additional specified disclosures by “foreign issuers” as defined in Rule 3b-4 promulgated under the Securities Exchange Act of 1934, as amended. The SEC will identify an issuer as a Commission-Identified Issuer as early as possible after the issuer files its annual report and on a rolling basis, and will impose an initial trading prohibition on an issuer as soon as practicable after it has been conclusively identified as a Commission-Identified Issuer for three consecutive years. To end an initial or subsequent trading prohibition, a Commission-Identified Issuer must certify that it has retained a registered public accounting firm that the PCAOB has determined it is able to inspect or investigate. To make that certification, the Commission-Identified Issuer must file financial statements that include an audit report signed by such a registered public accounting firm.

On March 30, 2022, as expected following its adoption of the Final Rules, the SEC added BeiGene, Ltd. to its conclusive list of issuers identified under the HFCAA, after being provisionally named as a Commission-Identified Issuer on March 8, 2022, following the filing of its annual report on Form 10-K with the SEC on February 28, 2022. Ernst & Young Hua Ming LLP, located in the PRC, served as our independent registered public accounting firm from 2014 to 2021, including for our annual report on Form 10-K for the year ended December 31, 2021 filed on February 28, 2022. However, as our global business has expanded, we have evaluated, designed and implemented business processes and control changes and built substantial organizational capabilities outside of the PRC. Therefore, on March 23, 2022, following a review process carried out by our audit committee, Ernst & Young Hua Ming LLP resigned as our independent registered public accounting firm for the audits of our financial statements and internal control over financial reporting to be filed with the SEC. On the same day, our audit committee approved the engagement of Ernst & Young LLP, located in Boston, Massachusetts, United States, as the Company’s independent registered public accounting firm for the audits of our financial statements and internal control over financial reporting for the fiscal year ending December 31, 2022 to be filed with the SEC. No changes were made to the accounting firms who audit our financial statements filed with the Shanghai Stock Exchange and the Hong Kong Stock Exchange, which will remain Ernst & Young Hua Ming LLP, located in Beijing, PRC, and Ernst & Young, located in Hong Kong, PRC, respectively.

We have evaluated, designed and implemented additional business processes and internal control changes which have enabled us to engage Ernst & Young LLP (United States), which is subject to PCAOB inspection requirements. Given that Ernst and Young LLP (United States) will serve as the principal accountant to audit our consolidated financial statements for the fiscal year ending December 31, 2022, to be included in the 2022 Form 10-K, to be filed with the SEC, we expect to be able to comply with the HFCAA and certify following the filing of our 2022 Form 10-K that we have retained a registered public accounting firm that the PCAOB has determined it is able to inspect or investigate, Ernst & Young LLP (United States), which should preclude a further finding by the SEC that we are a Commission-Identified Issuer and therefore the delisting of our American Depositary Shares from the NASDAQ Global Select Market.

However, these efforts may not be sufficient and ultimately may not be successful. We may also be subject to enforcement under the HFCAA, the rules implementing the act that may be adopted by the SEC, and any other similar legislation that may be enacted into law or executive orders that may be adopted in the future. Although we are committed to complying with the rules and regulations applicable to listed companies in the United States, we are currently unable to predict the potential impact on our listed status by any rules that may be adopted by the SEC under the HFCAA in the future. If we failed to comply with those rules, it is possible that our ADSs would be delisted. The risk and uncertainty associated with a potential delisting would have a negative impact on the price of our ADSs, ordinary shares and RMB Shares. Failure to adopt effective contingency plans may also have a material adverse impact on our business and the price of our ADSs, ordinary shares and RMB Shares.”

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

After reviewing your response to these comments, we may have additional comments. Part I · Item 1. Business, page 5
SEC asked (4)
Clearly disclose how you will refer to the holding company and subsidiaries when providing the disclosure throughout the document so that it is clear to investors which entity the disclosure is referencing and which subsidiaries or entities are conducting the business operations. For example, disclose, if true, that your subsidiaries conduct operations in China.
ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in future Exchange Act periodic reports to clearly disclose how the Company will refer to the holding company and subsidiaries when providing disclosure throughout the document so it is clear to investors which entity the disclosure is referencing and which subsidiaries or entities are conducting the business operations.
Rest of the answer

In this regard, the Company respectfully refers the Staff to page 5 of the 2021 Annual Report where the Company discloses that “Unless the context requires otherwise, references in this report to “BeiGene,” the “Company,” “we,” “us,” and “our” refer to BeiGene, Ltd., and its subsidiaries, on a consolidated basis.” The Company will revise future Exchange Act periodic reports to indicate that BeiGene, Ltd., is a Cayman Islands holding company with operations conducted by its subsidiaries.

Further, as depicted in Appendix A, the organization structure chart that will be included in future annual reports on Form 10-K provides the name and domicile of the Company’s selected subsidiaries. Where the context requires disclosure for any of the subsidiaries, the Company will refer to the specific subsidiary and, if applicable, it will be clearly defined. For example, on pages 23 to 26 of the 2021 Annual Report, where there was disclosure related to BeiGene Switzerland GmbH (BeiGene Switzerland), the Company specifically named and defined the subsidiary. Similarly, the Company did the same for BeiGene (Hong Kong) Co., Ltd. (BeiGene HK) in the 2021 Annual Report. The Company will continue to do this in its future Exchange Act periodic reports, as applicable. For your reference, please see Appendix B for the names and domicile of selected subsidiaries and how the Company may refer to them in future Exchange Act periodic reports.

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

After reviewing your response to these comments, we may have additional comments. Part I · Item 1. Business, page 5
SEC asked (5)
We note your discussion regarding dividends on page 99 and 111. Provide a clear description of how cash is transferred through your organization. Disclose your intentions to distribute earnings. Quantify any cash flows and transfers of other assets by type that have occurred between the holding company and its subsidiaries, and direction of transfer.
Rest of the question

Quantify any dividends or distributions that a subsidiary have made to the holding company and which entity made such transfer, and their tax consequences. Similarly quantify dividends or distributions made to U.S. investors, the source, and their tax consequences. Your disclosure should make clear if no transfers, dividends, or distributions have been made to date. Describe any restrictions on foreign exchange and your ability to transfer cash between entities, across borders, and to U.S. investors. Describe any restrictions and limitations on your ability to distribute earnings from the company, including your subsidiaries, to the parent company and U.S. investors.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in future annual reports on Form 10-K to describe how cash is transferred through the organization. In this regard, the Company undertakes to update the Business section in future annual reports on Form 10-K as follows, with necessary updates:

We are a holding company incorporated in the Cayman Islands with operations primarily conducted through subsidiaries in the United States, China, United Kingdom, Switzerland and Australia.
Rest of the answer

The intercompany flow of funds within the organization is effected through capital contributions and intercompany loans. Since our formation in 2010, BeiGene, Ltd. has raised over $10.0 billion in various public and private stock offerings as of December 31, 2021. Of this amount, $1.2 billion and RMB 4.9 billion have been transferred as capital contributions to its operating subsidiaries; and $79 million and RMB 3.1 billion have been transferred as intercompany loans to its operating subsidiaries. BeiGene, Ltd., by itself or through its affiliates, is also the holder or licensee and developer of biopharmaceutical patents. Certain of these patents have been transferred to operating subsidiaries for further development and commercialization. BeiGene’s wholly owned subsidiaries compensate each other for the intercompany provision of goods and services on an arm’s length basis. As of December 31, 2021, BeiGene, Ltd. held $5.8 billion in cash, cash equivalents and short-term investments which are available for future investment in its programs and in our operating subsidiaries. To date, BeiGene, Ltd. has not received any dividends or distributions from its operating subsidiaries.

Further, our board of directors has adopted a dividend policy which provides that we currently intend to retain all available funds and earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Subject to applicable law and our amended and restated articles of association, any future determination to pay dividends will be made at the discretion of our board of directors and may be based on a number of factors, including our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that our board of directors may deem relevant. This dividend policy reflects our board of directors’ current views on our financial and cash flow position. We intend to continue to review our dividend policy from time to time, and there can be no assurance that dividends will be paid in any particular amount, if at all, for any given period.

We have never declared or paid any dividends on our ordinary shares or any other securities. If we pay dividends in the future, in order for us to distribute dividends to our shareholders and holders of ADSs, we may rely to some extent on dividends distributed by our PRC subsidiaries. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us, and such distributions will be subject to PRC withholding tax. In addition, PRC regulations currently permit payment of dividends of a PRC company only out of accumulated distributable after-tax profits, as determined in accordance with our articles of association and the accounting standards and regulations in the PRC.

We may rely on dividends and other distributions on equity paid by our PRC subsidiaries for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders or to service any debt we may incur. If any of our PRC subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiaries may pay dividends only out of their respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund. In addition, registered share capital and capital reserve accounts are also restricted from withdrawal in the PRC, up to the amount of net assets held in each operating subsidiary. As of December 31, 2021, these restricted assets totaled $799.6 million.

Our PRC subsidiaries generate primarily all of their revenue in RMB, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may limit the ability of our PRC subsidiaries to use their RMB revenues to pay dividends to us. However, conversion of RMB to other currencies are permitted for the purpose of dividends according to the PRC’s regulations on Foreign Exchange Control.

Further, in response to the persistent capital outflow in the PRC and RMB’s depreciation against the U.S. dollar in the fourth quarter of 2016, the People’s Bank of China (PBOC) and China's State Administration of Foreign Exchange (SAFE) promulgated a series of capital control measures, including stricter vetting procedures for domestic companies to remit foreign currency for overseas investments, dividends payments and shareholder loan repayments. Such measures were relaxed in mid-2017 with the slowdown of the capital outflow and stabilizing of the RMB. However, the PRC government may revert to strengthen its capital controls, and more restrictions and substantial vetting process may be put forward by the SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.

The PRC Enterprise Income Tax Law (the “EIT Law”) and its implementation rules provide that China-sourced income of foreign enterprises, such as dividends paid by a PRC subsidiary to its equity holders that are non-PRC resident enterprises, will normally be subject to PRC withholding tax at a rate of 10%, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with China that provides for a reduced withholding rate arrangement and such non-PRC resident enterprises constitute the beneficiary of such income.

Pursuant to an arrangement between Mainland China and the Hong Kong Special Administrative Region (the “Hong Kong Tax Treaty”) and relevant tax regulations of the PRC, subject to certain conditions, a reduced withholding tax rate of 5% will be available for dividends from PRC entities provided that the recipient can demonstrate it is a Hong Kong tax resident and it is the beneficial owner of the dividends. The government adopted regulations in 2018 which stipulate that in determining whether a non-resident enterprise has the status as a beneficial owner, comprehensive analysis shall be conducted based on the factors listed therein and the actual circumstances of the specific case shall be taken into consideration. Specifically, it expressly excludes an agent or a designated payee from being considered as a “beneficial owner.” We own the PRC subsidiaries through BeiGene HK. BeiGene HK currently does not hold a Hong Kong tax resident certificate from the Inland Revenue Department of Hong Kong, and there is no assurance that the reduced withholding tax rate will be available.”

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

After reviewing your response to these comments, we may have additional comments. Part I · Item 1. Business, page 5
SEC asked (6)
We note your disclosure regarding potential PRC changes beginning on page 94. Disclose each permission or approval that you or your subsidiaries are required to obtain from Chinese authorities to operate your business and to offer securities to foreign investors.
Rest of the question

State whether you or your subsidiaries are covered by permissions requirements from the China Securities Regulatory Commission (CSRC), Cyberspace Administration of China (CAC) or any other governmental agency that is required to approve your operations, and state affirmatively whether you have received all requisite permissions or approvals and whether any permissions or approvals have been denied. Please also describe the consequences to you and your investors if you or your subsidiaries: (i) do not receive or maintain such permissions or approvals, (ii) inadvertently conclude that such permissions or approvals are not required, or (iii) applicable laws, regulations, or interpretations change and you are required to obtain such permissions or approvals in the future.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in the Business section of future annual reports on Form 10-K to disclose each permission or approval that the Company and its subsidiaries are required to obtain from Chinese authorities to operate our business and to offer securities to foreign investors, including whether the Company and its subsidiaries are covered by permissions requirements from the China Securities Regulatory Commission (CSRC), Cyberspace Administration of China (CAC) or any other governmental
Rest of the answer

agency that is required to approve our operations. The Company will also describe the consequences to it and its investors if the Company and its subsidiaries: (i) do not receive or maintain such permissions or approvals, (ii) inadvertently conclude that such permissions or approvals are not required, or (iii) applicable laws, regulations, or interpretations change and the Company is required to obtain such permissions or approvals in the future. Please refer to Appendix C for the risk factors the Company will include in future Exchange Act periodic reports.

The Company undertakes to update the Business section in future annual reports on Form 10-K as follows, with necessary updates:

“Permissions Required from the PRC Authorities for Our Operations

We conduct our business in the PRC through our PRC subsidiaries. Our operations in the PRC are governed by PRC laws and regulations. As of the date of this annual report, our PRC subsidiaries have obtained all requisite licenses and permits from the PRC government authorities that are material for their business operations in the PRC, including, among others, business licenses issued by local counterparts of the SAMR, drug manufacturing licenses, drug trade license, CTAs, drug registration certificates, import and export business qualifications and filings, licenses for use of experimental animals, pollutant discharge licenses and permits for urban sewage discharge into drainage pipe network. However, given the uncertainties of interpretation and implementation of relevant laws and regulations and the enforcement practice by government authorities, we cannot assure you that we have obtained all the permits or licenses required for conducting our business in the PRC.

In connection with our previous issuance of securities to foreign investors in stock markets outside the PRC, under current PRC laws, regulations and regulatory rules, as of the date of this annual report, we and our PRC subsidiaries, (i) are not required to obtain permissions from the CSRC, (ii) are not required to go through cybersecurity review by the Cyberspace Administration of China, or the CAC, and (iii) have not received or were denied such requisite permissions by any PRC authority. However, the PRC government has recently indicated an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers.

Further, as of the date of this annual report, we have not received any inquiry, notice, warning or sanction regarding obtaining approval, completing filing or other procedures in connection with offering our equity securities in overseas stock markets from the CSRC or any other Chinese regulatory authorities that have jurisdiction over our operations. However, there remains significant uncertainty as to the enactment, interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities, including the Draft Overseas Listing Regulations. If it is determined in the future that the approval of, filing or other procedure with the CSRC or any other regulatory authority is required for issuing our equity securities in overseas stock markets, it is uncertain whether we will be able to and how long it would take for us to obtain the approval or complete the filing or other procedure, despite our efforts. If we, for any reason, are unable to obtain or complete, or experience significant delays in obtaining or completing, the requisite relevant approval(s), filing or other procedure(s), we may face sanctions by the CSRC or other Chinese regulatory authorities as applicable. These regulatory authorities may impose fines and penalties on our operations in the PRC, limit our ability to pay dividends outside of China, limit our operations in the PRC, delay or restrict the repatriation of funds into the PRC or take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of our ADSs, ordinary shares and RMB Shares.”

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 1A. Risk Factors, page 54
SEC asked (7)
In your summary of risk factors, disclose the risks that your corporate structure and being based in or having the majority of the company’s operations in China poses to investors. In particular, describe the significant regulatory, liquidity, and enforcement risks.
Rest of the question

For example, specifically discuss risks arising from the legal system in China, including risks and uncertainties regarding the enforcement of laws and that rules and regulations in China can change quickly with little advance notice; and the risk that the Chinese government may intervene or influence your operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in your operations and/or the value of your securities. Acknowledge any risks that any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of your securities to significantly decline or be worthless.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in future relevant Exchange Act periodic reports to disclose the risks related to the Company’s corporate structure and of having significant operations in China poses to investors.
Rest of the answer

The Company will describe the significant regulatory, liquidity, and enforcement risks, including risks arising from the legal system in China; risks and uncertainties regarding the enforcement of laws and that rules and regulations in China can change quickly with little advance notice; and, the risk that the Chinese government may intervene or influence the Company’s operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in the Company’s operations and/or the value of the Company’s securities. Please refer to Appendix C for the risk factors the Company will include in future relevant Exchange Act periodic reports.

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 1A. Risk Factors, page 54
SEC asked (8)
We note your disclosure about the Holding Foreign Companies Accountable Act on page 96. Please expand your risk factors to disclose that you were identified by the Commission under the HFCAA. In addition, please update your disclosure to reflect that the Commission adopted rules to implement the HFCAA and that, pursuant to the HFCAA, the PCAOB has issued its report notifying the Commission of its determination that
Rest of the question

it is unable to inspect or investigate completely accounting firms headquartered in mainland China or Hong Kong.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in future relevant Exchange Act periodic reports to disclose that the Company was identified by the Commission under the HFCAA. In addition, the Company will update its disclosure to reflect that the Commission adopted rules to implement the HFCAA and that, pursuant to the HFCAA, the PCAOB has issued its report notifying the Commission of its determination that it is unable to inspect or investigate completely accounting firms headquartered in mainland China or Hong
Rest of the answer

Kong. The Company also advises the Staff that it plans to include new risk factor disclosures in the next quarterly report on Form 10-Q that will be filed on Monday, May 9, 2022, which discusses these risks, discloses that the Company was identified by the Commission under the HFCAA and the steps the Company has taken to address the HFCAA, including appointing Ernst & Young LLP (USA) as the Company’s independent registered public accounting firm for the year ending December 31, 2022 for its filings with the SEC. Please refer to Appendix D for the risk factors the Company will include in the next quarterly report on Form 10-Q.

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 1A. Risk Factors, page 54
SEC asked (9)
Given the Chinese government’s significant oversight and discretion over the conduct of your business, please revise to highlight separately the risk that the Chinese government may intervene or influence your operations at any time, which could result in a material change in your operations and/or the value of your securities.
Rest of the question

Also, given recent statements by the Chinese government indicating an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in Chinabased issuers, acknowledge the risk that any such action could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of your securities to significantly decline or be worthless.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in future relevant Exchange Act periodic reports to highlight the risk that the Chinese government may intervene or influence the Company’s operations at any time, which could result in a material change in our operations and/or the value of our securities.
Rest of the answer

Also, given recent statements by the Chinese government indicating an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in Chinabased issuers, the Company will acknowledge the risk that any such action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of our securities to significantly decline or be worthless. Please refer to Appendix C for the risk factors the Company will include in future Exchange Act periodic reports.

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 1A. Risk Factors, page 54
SEC asked (10)
We note your discussion regarding the Cyberspace Administration of China on page 90. In light of recent events indicating greater oversight by the Cyberspace Administration of China (CAC) over data security, particularly for companies seeking to list on a foreign exchange, please revise your disclosure to explain how this oversight impacts your business and your securities and to what extent you believe that you are
Rest of the question

compliant with the regulations or policies that have been issued by the CAC to date. In addition, please update the disclosure in this risk factor to reflect that the final version of the revisions to the existing Measures for Cybersecurity Review came into effect on February 15, 2022. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

ONC answered
The Company respectfully acknowledges the Staff’s comment, and advises the Staff that the Company will revise its disclosure in future relevant Exchange Act periodic reports to explain how the Cyberspace Administration of China’s oversight impacts the Company’s business and its securities, including the extent to which the Company believes it has been compliant with the regulations and policies that have been issued by the CAC to date.
Rest of the answer

Please refer to Appendix C for the risk factors the Company will include in future Exchange Act periodic reports.

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact the undersigned ([email protected] or 857-327-8286).

Read in the reply
In its next report

First report after the company's reply of May 6, 2022: 10-Q filed May 9, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Part I · Item 1. Business, page 5
SEC asked (1)
We note your response to prior comment 5 including your description of how cash is transferred through your organization. Please revise to disclose whether cash generated from one subsidiary is used to fund another subsidiary’s operations. For example, please state whether you have ever faced difficulties or limitations on your ability to transfer cash between subsidiaries.
Rest of the question

Please update your disclosure to disclose if you have specific cash management policies and procedures in place that dictate how funds are transferred through your organization and if applicable, describe these policies and procedures in greater detail.

ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that it will revise the Business section of future annual reports on Form 10-K to disclose whether cash generated from one subsidiary is used to fund another subsidiary’s operations, including relevant disclosures on material difficulties or limitations the Company may face in its ability to transfer cash between subsidiaries. Further, the Company will disclose its cash management policies and procedures.
Rest of the answer

The Company undertakes to update the Business section in future annual reports on Form 10-K as follows, with necessary updates:

“Cash Management Policies and Procedures

Under our Capitalization and Financing Policy, the frequency and amount of intercompany transfers of funds is determined based on the working capital needs of our subsidiaries and intercompany transactions, and is subject to internal approval processes and funding arrangements. Our management reviews and monitors our cash flow forecast and working capital needs of our subsidiaries on a regular basis. In addition, capital contributions and intercompany loan arrangements are subject to local jurisdiction and banking regulations. In this regard, we have not faced difficulties or limitations in our ability to transfer cash between subsidiaries in any of our operating jurisdictions.

During the normal course of our business, cash is transferred between our subsidiaries via wire transfer to and from bank accounts to pay certain business expenses. Cash is maintained by BeiGene, Ltd. in its bank account and transferred to its subsidiaries when necessary to strengthen our business capabilities, such as paying for new office development, or marketing expenses. In addition, cash may be used by BeiGene, Ltd. to meet corporate expenses such as audit fees, attorneys’ fees, stock exchange listing fees, IR/PR expenses, research and development costs and corporate administrative support expenses.

Cash is transferred between subsidiaries in the form of capital contributions or through intercompany advances or loans, as follows:

•Cash may be transferred between BeiGene HK and its operating subsidiaries in mainland China through intercompany loans and capital contributions, and there are currently no restrictions on transferring funds between BeiGene HK and its subsidiaries in mainland China. Cash generated from BeiGene HK is used to fund operations of its subsidiaries, and no funds were transferred from BeiGene HK’s subsidiaries in mainland China to fund operations of other BeiGene subsidiaries outside of mainland China for the year ended on December 31, 2020 and December 31, 2021. For the year ended December 31, 2020 and December 31, 2021, the amount of cash transferred between BeiGene HK and its subsidiaries in mainland China was $661 million and $44 million, respectively.

•Cash may be transferred between BeiGene UK and/or BeiGene Switzerland and their respective operating subsidiaries through intercompany fund advances and capital contributions. There are currently no restrictions on transferring funds between BeiGene UK or BeiGene Switzerland and their respective operating subsidiaries. Cash generated from BeiGene UK and BeiGene Switzerland are used to fund operations of their respective subsidiaries, and no funds were transferred from BeiGene UK’s subsidiaries or from BeiGene Switzerland’s subsidiaries to fund operations of other BeiGene subsidiaries (such as BeiGene HK and its subsidiaries in mainland China) for the year ended on December 31, 2020 and December 31, 2021. For the year ended December 31, 2020 and December 31, 2021, the amount of cash transferred between BeiGene UK and BeiGene Switzerland to their respective subsidiaries was $0 and $97,000.00 and $2 million and $25 million, respectively.”

Read in the reply
In its next report

First report after the company's reply of Jun 3, 2022: 10-Q filed Aug 8, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Part I · Item 1. Business, page 5
SEC asked (2)
We note your response to prior comment 6. Please revise your disclosure to explicitly address the consequences to you and your investors if you or your subsidiaries inadvertently conclude that such permissions or approvals are not required.
ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that some of the risks and consequences that are applicable to variable interest entities (“VIEs”) do not apply to the Company because it does not use VIEs in China or elsewhere. Unlike other U.S. listed companies with operations in China, the Company does not conduct business in China through VIEs, and is therefore not subject to the risks of VIE business operations, corporate structure or contractual arrangements.
Rest of the answer

However, in response to the Staff’s comments, we will further revise the disclosure the Company includes in the Business section of future annual reports on Form 10-K to explicitly address the consequences applicable to the Company and its investors if the Company or its subsidiaries inadvertently concludes that permissions from the China Securities Regulatory Commission (CSRC), Cyberspace Administration of China permissions China (CAC) or any other governmental agency to approve our operations are not required. Further, the Company will make conforming changes to future relevant risk factor disclosures, as applicable.

The Company undertakes to update the Business section in future annual reports on Form 10-K as follows, with necessary updates:

“Permissions Required from the PRC Authorities for Our Operations

We conduct our business in the PRC through our PRC subsidiaries. Our operations in the PRC are governed by PRC laws and regulations. As of the date of this annual report, our PRC subsidiaries have obtained all requisite licenses and permits from the PRC government authorities that are material for their business operations in the PRC, including, among others, business licenses issued by local counterparts of the SAMR, drug manufacturing licenses, drug trade licenses, CTAs, drug registration certificates, import and export business qualifications and filings, licenses for use of experimental animals, pollutant discharge licenses and permits for urban sewage discharge into drainage pipe networks. No material permissions have been denied to us by relevant government authorities in China. As of the date of this annual report, we do not operate our businesses in China or elsewhere through variable interest entities, or VIEs, and therefore are not subject to risks associated with contractual arrangements with VIEs. As of the date of this annual report, we have not received any inquiry, notice, warning, or sanctions regarding our business operations and corporate structure from the CSRC, CAC or any other PRC governmental agency that would have a material impact on our business, results of operations or financial condition. However, given the uncertainties of interpretation and implementation of relevant laws and regulations and the enforcement practice by government authorities, we cannot assure you that we have obtained all the permits or licenses required for conducting our business in the PRC. If (i) we have inadvertently concluded that such permissions, approvals, licenses or permits have been acquired or are not required, or (ii) applicable laws, regulations, or interpretations change and we are required to obtain such permissions, approvals, licenses or permits in the future, then we may have to expend time and costs to procure them. If we are unable to do so on commercially reasonable terms or in a timely manner, it could cause significant disruption to our business operations and damage our reputation, which would in turn have a material adverse effect on our business, results of operations and financial condition.

In connection with our previous issuance of securities listed on the NASDAQ Global Select Market and Hong Kong Stock Exchange, under current PRC laws, regulations and regulatory rules, as of the date of this annual report, we and our PRC subsidiaries, (i) are not required to obtain permissions from the CSRC, (ii) are not required to go through cybersecurity review by the Cyberspace Administration of China, or the CAC, and (iii) have not received or were denied such requisite permissions by any PRC authority. However, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the “Opinions on Intensifying Crack-Down on Illegal Securities Activities,” or the Opinions, which were made available to the public in July 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities and the need to strengthen the supervision over overseas listings by Chinese companies. We have been closely monitoring and will continue to monitor regulatory developments in China regarding any necessary approvals from the CSRC or other PRC governmental authorities required for offerings on the NASDAQ Global Select Market or Hong Kong Stock Exchange.

As of the date of this annual report, we have not received any inquiry, notice, warning or sanction regarding obtaining approval, completing filings or other procedures in connection with offering our equity securities on the NASDAQ Global Select Market or Hong Kong Stock Exchange from the CSRC or any other PRC governmental or regulatory authorities that have jurisdiction over our operations. However, there remains significant uncertainty as to the enactment, interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities, including the Draft Overseas Listing Regulations. If it is determined in the future that the approval of, filing or other procedures with the CSRC or any other Chinese governmental or regulatory authority is required for issuing our equity securities the NASDAQ Global Select Market or Hong Kong Stock Exchange, it is uncertain whether we will be able to and how long it would take for us to obtain the approval or complete the filings or other procedures, despite our efforts. If we, for any reason, are unable to obtain or complete, or experience significant delays in obtaining or completing, the requisite relevant approval(s), filing or other procedure(s), we may face sanctions by the CSRC or other Chinese regulatory authorities. These regulatory authorities may impose fines and penalties on our operations in the PRC, limit our ability to pay dividends outside of China, limit our operations in the PRC, delay or restrict the repatriation of funds into the PRC or take other actions that could have a material adverse effect on our business, financial condition, and results of operations. According to Relevant Officials of the CSRC Answered Reporter Questions (“CSRC Answers”), after the Draft Overseas Listing Regulations are implemented, the CSRC will formulate and issue guidance for filing procedures. This is an ongoing process that is expected to take some time to become effective. Since the Draft Overseas Listing Regulations have not yet come into effect, we are currently unaffected.”

The Company undertakes to provide risk factor disclosure in future annual reports on Form 10-K as follows, with necessary updates:

“The approval of, or filing or other procedures with, the CSRC or other Chinese regulatory authorities may be required in connection with issuing our equity securities, and, if required, we cannot predict whether we will be able, or how long it will take us, to obtain such approval or complete such filing or other procedures. If the Draft Overseas Listing Regulations is adopted as currently proposed and if we fail to complete a filing with the CSRC, our offering application may be discontinued and we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council. In severe circumstances, the business of our PRC subsidiaries could be suspended and their business qualifications and licenses may be revoked, which would have a material adverse effect on our business, financial condition, and results of operations.

In July 2021, the General Office of the Communist Party of China Central Committee and the State Council jointly promulgated the Opinions on Intensifying Crack Down on Illegal Securities Activities (the “Opinions”), pursuant to which Chinese regulators are required to accelerate rulemaking related to the issuance and listing of securities outside of China, and update the existing laws and regulations related to data security, cross-border data flow, and administration of classified information. The Opinions emphasized the need to strengthen the administration over illegal securities activities and the need to strengthen the supervision over overseas listings by Chinese companies. Given the current PRC regulatory environment, it is uncertain when and whether we or our PRC subsidiaries will be required to obtain permission from the PRC government to offer securities on the NASDAQ Global Select Market or Hong Kong Stock Exchange in the future, and even when such permission is required, whether it will be denied or rescinded.

Numerous regulations, guidelines and other measures have been or are expected to be adopted under the umbrella of or in addition to the Cyber Security Law (as defined below) and Data Security Law (as defined below). As there are still uncertainties regarding the interpretation and implementation of such regulatory guidance, we cannot assure investors that we will be able to comply with new regulatory requirements relating to our future capital-raising activities outside of China and we may become subject to more stringent requirements with respect to matters including data privacy and cross-border investigation and enforcement of legal claims.

Furthermore, in December 2021, the CSRC promulgated the Draft Overseas Listing Rules, which, among other things, require certain companies to make filings for offerings and listing in stock markets outside of China if such companies meet the criteria set forth in the Draft Overseas Listing Rules. As the Draft Overseas Listing Rules were released only for public comment, the final version and the effective date may be subject to change with substantial uncertainty. According to Relevant Officials of the CSRC Answered Reporter Questions (“CSRC Answers”), after the Draft Overseas Listing Regulations are implemented, the CSRC will formulate and issue guidance for filing procedures. This is an ongoing process that is expected to take some time to become effective. Since the Draft Overseas Listing Regulations have not yet come into effect, we are currently unaffected.

Additionally, according to the CSRC Answers, only new initial public offerings and follow-on offerings by Chinese companies listed outside the PRC will be required to go through the filing process; other companies listed outside the PRC, such as us, will be allowed a sufficient transition period to complete their filing procedures, which means that after the effectiveness of the Draft Overseas Listing Regulations, we may have to go through the filing process for any follow-on offerings we conduct on the NASDAQ Global Select Market or Hong Kong Stock Exchange. If this were to happen, we would expect to be given a sufficient transition period to complete these filings. If the Draft Overseas Listing Regulations is adopted as currently proposed, and if we fail to complete a filing with the CSRC for any of our follow-on offerings or fall within any of the circumstances where our follow-on offerings are prohibited by the State Council, our offering application may be discontinued and we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council. In severe circumstances, the business of our PRC subsidiaries could be suspended and their business qualifications and licenses may be revoked, which would have a material adverse effect on our business, financial condition, and results of operations.

As of the date of this report, we have not received any inquiry, notice, warning or sanction regarding obtaining approval, completing filing or other procedures in connection with offering our equity securities on the NASDAQ Global Select Market or Hong Kong Stock Exchange from the CSRC or any other Chinese regulatory authorities that have jurisdiction over our operations. However, there remains significant uncertainty as to the enactment, interpretation and implementation of regulatory requirements related to securities offerings and other capital markets activities outside of China. If it is determined in the future that the approval of, filing or other procedure with the CSRC or any other regulatory authority is required for issuing our equity securities on the NASDAQ Global Select Market or Hong Kong Stock Exchange, it is uncertain whether we will be able to and how long it would take for us to obtain the approval or complete the filing or other procedure, despite our best efforts. If we, for any reason, are unable to obtain or complete, or experience significant delays in obtaining or completing, the requisite relevant approval(s), filing or other procedure(s), we may face sanctions by the CSRC or other Chinese regulatory authorities. These regulatory authorities may impose fines and penalties on our operations in China, limit our ability to pay dividends outside of China, limit our operations in China, delay or restrict the repatriation of funds into China or take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of our ADSs, ordinary shares, and RMB Shares. In addition, if the CSRC or other regulatory authorities later promulgate new rules requiring that we obtain approvals or complete filing or other procedures for any future public offerings on the NASDAQ Global Select Market or Hong Kong Stock Exchange, we may be unable to obtain a waiver of such requirements, if and when procedures are established to obtain such a waiver. Any uncertainties and/or negative publicity regarding such a requirement could have a material adverse effect on the trading price of our ADSs, ordinary shares, and RMB Shares.

To operate our general business activities currently conducted in China, each of our Chinese subsidiaries is required to obtain a business license from the local counterpart of the State Administration for Market Regulation (“SAMR”). Each of our Chinese subsidiaries has obtained a valid business license from the local counterpart of the SAMR, and no application for any such license has been denied. The pharmaceutical industry in which we operate is also highly regulated in China. Our Chinese subsidiaries are required to obtain applicable licenses from Chinese government authorities for our operations in China, including drug manufacturing licenses, drug trade license, clinical trial authorizations, drug registration certificates, import and export business qualifications and filings, licenses for use of experimental animals, pollutant discharge licenses and permits for urban sewage discharge into drainage pipe network. We believe our PRC subsidiaries have obtained all applicable licenses and permits which are material to our business operations in China.”

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact the undersigned ([email protected] or 857-327-8286).

Read in the reply
In its next report

First report after the company's reply of Jun 3, 2022: 10-Q filed Aug 8, 2022 ↗, against the 10-Q filed Nov 4, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Apr 11, 2022, closing letter, 2022-06-15

Form 10-K for the Fiscal Year Ended December 31, 2020

2021-09-21 to 2022-01-28 · 10 questions · 2 letters from the SEC, 2 from the company
Review closed 2022-01-28
ClimateResults discussion (MD&A)
SEC asked (1)
There have been significant developments in federal and state legislation and regulation and international accords regarding climate change. We note that you have not discussed the impact of pending or existing climate change-related legislation, regulations, and international accords in your SEC filing.
Rest of the question

Please revise your disclosure to identify material existing climate change-related legislation, regulations, and international accords and any material effect on your business, financial condition, and results of operations.

ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company is focused on its environmental stewardship. As a company working to find a cure for cancer and other life-threatening diseases, we are diligent in our efforts to comply with all environmental laws and regulations. However, we are not aware of any existing or pending climate change-related legislation, regulations, and international accords that would have a material effect on the Company’s financial condition or results of operations for the reporting periods.
Rest of the answer

Similarly, we are not aware of any specific risks that would materially impact the Company as a result of climate change legislation, regulation or international accords. For example, the Company’s operations are not particularly sensitive to greenhouse gas legislation or regulation (such as those applicable to the energy sector) or those promulgated to regulate products that emit greenhouse gases (such as those applicable to the transportation sector) or subject to the “cap and trade” system. However, we will continue to monitor for future climate change legislation, regulations, and international accords and will disclose relevant information, if material.

Read in the reply
SEC asked (2)
In your CSR reports, you describe climate-related projects, intended to reduce emissions, conserve resources, and minimize your impact on the environment. Your proxy statement also references investments in environmental sustainability. Please revise your disclosure to identify any material past and/or future capital expenditures for climate-related projects. If material, please quantify these expenditures.
ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the historical capital expenditures incurred related to the development and launch of the initiatives discussed on page 33 of the Company’s 2020 ESG Report and summarized below have not been material in the context of the Company’s total capital expenditures or its overall business and financial position.

In 2019, at our Suzhou plant we introduced:

•A centrifugal variable frequency chiller that automatically adjusts load to meet operational requirements, resulting in a roughly 10% energy savings;

•An
Rest of the answer

upgraded condensate water cooling control system, saving around 3,500 tonnes of water per year; and

•The reuse of purified run-off drainage as cooling water in lieu of municipal water for the cooling condensate system, saving about 17,000 tonnes of water per year.

Our capital expenditures for climate-related projects were approximately $[****] for the fiscal year ended December 31, 2019, which the Company does not consider material.

In 2020, we upgraded to a more efficient steam trap, saving about 800 tonnes of steam per year and re-classified wasted print packing material to non-hazardous waste. In the Guangzhou plant, we cut the production time of a batch of biologics from seven to four days while doubling yields from each batch. In addition to increasing production capacity, these changes are estimated to have reduced water use and waste generation by more than 50% annually. Our capital expenditures for climate-related projects were approximately $[****] for the fiscal year ended December 31, 2020, which the Company does not consider material.

We are also building a high-density warehouse with two-and-a half times the storage capacity of our previous warehouse, reducing electricity costs for temperature control by about 55%. We estimate that our capital expenditures for climate-related projects will be approximately $[****] and $[****] and not be material for fiscal years 2021 and 2022, respectively.

Read in the reply
SEC asked (3)
We note your disclosure in your CSR reports that among your main impacts on the environment and natural resources are emissions generated and the use of natural resources in the process of research and development as well as manufacturing.
Rest of the question

To the extent applicable and material, discuss the indirect consequences of climate-related regulation or business trends, such as the following: • decreased demand for goods or services that produce significant greenhouse gas emissions or are related to carbon-based energy sources; • increased demand for goods that result in lower emissions than competing products; • increased competition to develop innovative new products that result in lower emissions; and • any anticipated climate-related reputational risks resulting from operations or products that you sell.

ONC answered
The Company operates research and development and manufacturing facilities in China in Beijing, Shanghai, Suzhou and Guangzhou. In this regard, we considered whether our impacts on the environment and natural resources, such as the emissions generated and the use of natural resources in the process of research and development as well as manufacturing, may create new opportunities or risks that may have indirect consequences for the Company, including, among other things, increasing competition, changes in demand for services related to carbon based energy sources and reputational damage
Rest of the answer

relating to greenhouse gas emissions. Based on the nature of our operations, we have not identified potential direct or indirect consequences of climate change that have had or would have a material effect on our financial condition or results of operations. However, we will continue to monitor for future indirect consequences and will disclose relevant information, if material.

Read in the reply
SEC asked (4)
If material, discuss the significant physical effects of climate change on your operations and results. This disclosure may include quantification of material weather-related damages to your property or operations and any weather-related impacts on the cost or availability of insurance.
ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that we have not had material weather-related damages to our property or operations or any material impacts on the cost or availability of insurance. We will continue to monitor for future material weather-related damages to our property and operations and any weather-related impacts on the cost or availability of insurance and will disclose relevant information, if material.
Read in the reply
SEC asked (5)
Disclose the material effects of transition risks related to climate change that may affect your business, financial condition, and results of operations, such as policy and regulatory changes that could impose operational and compliance burdens, market trends that may alter business opportunities, credit risks, or technological changes that may affect your business as a result of climate change.
ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that, to date, transition related to climate change has not materially affected our business, financial condition, and results of operations. We will continue to monitor for developments related to transition risks and tailored disclosure will be added to the extent climate change transition risks are determined to have a material impact on our business, financial condition, and results of operations.
Read in the reply
SEC asked (6)
Quantify any material increased compliance costs related to climate change.
ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that, to date, the costs associated with complying with environmental laws have been customary and normal for a company of similar capacity in similar locations, and not material to an understanding of the Company’s business, financial condition, or results of operations. Our facilities and operations are subject to various environmental laws and regulations.
Rest of the answer

We undergo periodic internal audits relating to environmental, health and safety requirements in order to maintain compliance with applicable laws and regulations in each of the jurisdictions in which we operate. We have made, and continue to make, expenditures necessary to comply with applicable environmental laws. Currently, we do not believe that the costs for complying with such laws and regulations have been or will be material to our business, financial condition and results of operations. However, we will continue to monitor for future regulatory developments and the compliance costs related to climate change and will disclose relevant information, if material.

While we believe that climate change could present risks to our business, including increased operating costs due to additional regulatory requirements, physical risks to our facilities, water limitations, and disruptions to our supply chain, we do not believe these risks are material to our business in the near term. Specifically, during the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on environmental, health and safety expenses, which the Company does not consider material. We had no material capital costs related to compliance with climate change during the years ended December 31, 2020 and 2019. To the extent these costs become material to an understanding of the Company in the future, we will include such disclosure in our filings.

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact the undersigned ([email protected] or 857-327-8286).

Read in the reply
General
SEC asked (1)
We note your response to our prior comment number 1. As it relates to providing tailored disclosure, please explain in greater detail how the nature of your business supports your conclusion that pending or existing climate change-related legislation, regulations, and international accords will not have a material impact and the process through which existing or pending climate change-related legislation,
Rest of the question

regulations and international accords are evaluated. In addition, tell us how you considered addressing difficulties in assessing the timing and effect of pending legislation or regulation.

ONC answered
The Company acknowledges the Staff’s comment and respectively advise the Staff that based on our assessment, we believe that both domestic and international legislation to address climate change by reducing greenhouse gas emissions and establishing a price on carbon could create increases in energy costs and price volatility.
Rest of the answer

Specifically, we considered governmental greenhouse gas emission initiatives that include, among others, the December 2015 Paris Agreement, which was the outcome of the 21st session of the Conference of the Parties under the United Nations Framework Convention on Climate Change. The Paris Agreement, which was signed by nearly 200 nations, including the United States, Canada, and China, entered into force in late 2016 and sets out a goal of limiting the average rise in temperatures for this century to below 2 degrees Celsius. Each signatory is expected to develop its own plan (referred to as a Nationally Determined Contribution) for reaching that goal.

In the U.S., there currently is little action on climate change policy at the Congressional level, but such policy is being actively conducted by the Executive Branch – by the U.S. Environmental Protection Agency under the auspices of the Clean Air Act of 1963, as amended. In addition, climate change policy is being pursued through various initiatives by several U.S. states. In other countries, significant efforts include the national cap-and-trade systems of Australia and New Zealand, carbon tax programs in various European and Scandinavian countries, a carbon tax introduced in the Canadian province of British Columbia, the cap-and-trade program to reduce greenhouse gas emissions by the nations involved in the European Union’s Emissions Trading Scheme, a pilot cap-and-trade scheme in seven cities in China, and a range of efforts undertaken by nations that have signed on to the Kyoto Protocol and the Paris Agreement. The policies span a range of regulatory approaches, including technology mandates, performance standards, emissions pricing, and reporting of greenhouse gas emissions.

Our manufacturing processes require that we purchase significant quantities of energy from third parties, which results in the generation of greenhouse gases, either directly on-site or indirectly at electric utilities. While we believe that existing and proposed legislative efforts to control or limit greenhouse gas emissions could affect our energy source and supply choices as well as increase the cost of energy and raw materials derived from sources that generate greenhouse gas emissions, we do not believe these are material to our business. Specifically, during the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on energy source, including water, electricity, gas and steam, which the Company does not consider material. We had no material capital costs related to compliance with climate change during the years ended December 31, 2020 and 2019. To the extent these costs become material to an understanding of the Company in the future, we will include such disclosure in our filings.

It is possible that future legislation or regulation addressing climate change, including in response to the Paris Agreement or any new international agreements, could adversely affect our operating activities, energy, raw material and transportation costs, results of operations, liquidity or capital resources, and these effects could be material or adversely impact our competitive advantage. At the present time, we cannot predict the prospective impact of these future legislation or regulation addressing climate change on our results of operations, liquidity or capital resources, or whether any such effects could be material to us. However, we are confident we will continue to make progress on our ambitions, as disclosed in our annual ESG Report, and to regularly and systemically engage with our stakeholders and report on goals and ambitions in our future annual ESG Reports. In addition, we continue to integrate climate change considerations into our ongoing business planning, and in 2022, we plan to engage a third-party consultant to help us conduct a climate-specific risk assessment, following the Task Force on Climate-related Financial Disclosures (“TCFD”) framework. To the extent our climate-related risk assessments become material to an understanding of the Company’s results of operations and financial condition in the future, we will include such disclosure in our SEC filings.

Read in the reply
General
SEC asked (2)
We note your response to our prior comment number 3, which states that based on the nature of your operations you have not identified potential direct or indirect consequences of climate change that have had or would have a material effect on your financial condition or results of operations.
Rest of the question

Please describe how you concluded the indirect consequences you considered in your analysis were not material, including by describing the nature of your operations. Your response should address each of the items from our prior comment.

ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that, with respect to potential indirect consequences of climate change on our financial conditions and results of operations, we considered whether any the following have had a material impact:

a)decreased demand for goods or services that produce significant greenhouse gas emissions or are related to carbon-based energy sources;

b)increased demand for goods that result in lower emissions than competing products;

c)increased competition to develop innovative new products that result in lower emissions; and
Rest of the answer

d)any anticipated climate-related reputational risks resulting from operations or products that we sell.

As further discussed below, based on the nature of our operations as a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, we have not identified potential direct or indirect consequences of climate change that have had or would have a material effect on our financial condition or results of operations. However, we are committed to reducing our carbon emissions as reported in our annual ESG Report and will continue to monitor for future indirect consequences and will disclose relevant information, if material. To this end, early this year, we hired a Senior Director, Global Reputation and ESG Lead to help us develop and implement a global ESG strategy including a climate action plan. Additionally, in 2022, we plan to engage a third-party consulting firm to, among other things:

•Measure and analyze BeiGene’s global Scope 1 and 2 energy, greenhouse gas emissions, water, waste, and packaging footprint from offices, distribution centers, research and development laboratories, and manufacturing facilities for fiscal year 2022, which will establish a baseline year for the Company’s global emissions and footprint;

•Conduct an assessment of Scope 3 emissions to determine areas of material emissions and inform future efforts on reducing greenhouse gas emissions and footprint;

•Develop a comprehensive global carbon reduction strategy, including forward-looking targets; and

•Assess climate-related risks and opportunities using the TCFD framework.

We will provide the result of these assessments in our future annual ESG Reports. To the extent any of the assessments are material to an understanding of the Company’s business, financial condition or results of operations, we will include relevant disclosure in our future SEC filings.

Decreased demand for goods or services that produce significant greenhouse gas emissions or are related to carbon-based energy sources

Annual disclosure of our Scope 1 and Scope 2 GHG emissions for certain facilities, as well as other related data, can be found in our annual ESG Report. Our 2018 data covers major operations in China, including our Beijing laboratory, Beijing office building, Suzhou factory and Suzhou office building for the period from January 1, 2018 to December 31, 2018. Other small offices in China, overseas offices and facilities under construction are not included. Our 2019 ESG Report covers the major operations of BeiGene, including our Beijing R&D center, Suzhou and Guangzhou plants, all office buildings located in China and an office in the United States for the period from January 1, 2019 to December 31, 2019. Our 2020 ESG Report covers the major operations of BeiGene, including our Beijing and Shanghai R&D centers, Suzhou and Guangzhou manufacturing facilities, all office buildings located in China, and the Cambridge office in the United States for the period from January 1, 2020 to December 31, 2020.

As we noted in our response to comment 1, our manufacturing processes require that we purchase significant quantities of energy from third parties, which results in the generation of greenhouse gases. During the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on energy sources. Additionally, our manufacturing processes also result in greenhouse gas emissions from certain chemical reactions necessary to manufacture our clinical-stage and commercial drug products as well as the handling of waste. During the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on the handling of waste and hazardous materials. The Company does not consider these costs material.

With respect to transportation, goods and services that produce significant greenhouse gas emissions or those related to carbon-based energy sources primarily come from burning fossil fuel for vehicles we rent and use commercially. During the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on rental vehicles, which the Company does not consider material.

Given the nature of our operations, any decreased demand for goods or services that produce significant greenhouse gas emissions resulting from any effect of carbon pricing, diesel and petrol vehicle restrictions, and higher costs of energy have not had any material impact on the Company, as discussed above.

Increased demand for goods that result in lower emissions than competing products

Given the nature of our operations as a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, the increased demand for goods that result in lower emissions than competing products have not had any material impact on the Company and will not be material for fiscal years 2021 and 2022, respectively. As disclosed in our 2020 ESG Report, the Company has been investing in energy management projects, which cut operating costs and contribution to global energy reduction. As noted in our response letter dated October 29, 2021, during the year ended December 31, 2019 and December 31, 2020, the Company incurred approximately $[****] and $[****] on capital expenditures for climate-related projects. We estimate that our capital expenditures for climate-related projects will be approximately $[****] and $[****] and not be material for fiscal years 2021 and 2022, respectively.

Additionally, during the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on electricity and steam, a portion of which include renewal energy. Similarly, during the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on handling waste. Further, the Company estimates that it will spend approximately $[****] and $[****] on its recycling policy in fiscal years 2021 and 2022, respectively. The Company does not consider these costs material.

Increased competition to develop innovative new products that result in lower emissions

Based on the nature of our operations as a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, we have not experienced any increased competition to develop innovative new products that result in lower emissions. Our research organization has delivered ten molecules into the clinic in our first ten years, including our two lead commercial medicines, BRUKINSA®, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers, and tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers. We have received regulatory approvals to market BRUKINSA® in the world’s three largest pharmaceutical markets, the United States, China and the European Union, and tislelizumab in China, with an established, science-based commercial organization.

We have built state-of-the-art biologic and small molecule manufacturing facilities in China to support the potential future demand of our products, and we also work with high quality contract manufacturing organizations to manufacture our internally developed clinical and commercial products. We follow strict quality control standards in testing, manufacturing, packaging, storage, and distribution of our medicines and are committed to maintaining high standards on safety and product quality. Our research laboratories and manufacturing facilities are currently located solely in China, with our operations in the United States, Europe, Australia and other locations around the world conducted from rented, commercially available office space. However, we recently announced that we have acquired a 42-acre site at the Princeton West Innovation Campus in Hopewell, N.J. and plan to build a new state-of-the-art manufacturing campus and clinical R&D center there.

Any anticipated climate-related reputational risks resulting from operations or products that we sell

Since 2018, we have conducted an annual materiality assessment to identify the ESG issues most important to our stakeholders and business. These assessments are reviewed annually and published in our 2018 annual report as well as our 2019 and 2020 ESG reports, including disclosure of our energy use, greenhouse gas emissions, water consumption, waste, and packaging use across some of our sites. Our 2018 data covers major operations in China, including our Beijing laboratory, Beijing office building, Suzhou factory and Suzhou office building for the period from January 1, 2018 to December 31, 2018. Other small offices in China, overseas offices and facilities under construction are not included. Our 2019 ESG Report covers the major operations of BeiGene, including our Beijing R&D center, Suzhou and Guangzhou plants, all office buildings located in China and an office in the United States for the period from January 1, 2019 to December 31, 2019. Our 2020 ESG Report covers the major operations of BeiGene, including our Beijing and Shanghai R&D centers, Suzhou and Guangzhou manufacturing facilities, all office buildings located in China, and the Cambridge office in the United States for the period from January 1, 2020 to December 31, 2020. We expect to report Scope 1 and 2 GHG emissions as well as water consumption, waste and packaging use for all of our facilities in our 2021 ESG Report.

To date, we have not observed any impact on the Company’s reputation from this publicly available data nor based on our results of operations and product revenue as discussed in the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q. Additionally, our stock price has steadily increased from $100.81 per share on January 2, 2018 to $314.14 per share on December 4, 2021.

We began generating product revenue in September 2017 through our in-license agreement with BMS to distribute the approved cancer therapies REVLIMID®, VIDAZA®, and ABRAXANE® in China. Following approval from the FDA in November 2019, we launched our first internally developed medicine, BRUKINSA®, in the United States. We launched our second internally developed medicine, tislelizumab, in China in March 2020 and in June 2020, we launched BRUKINSA® in China. We currently have 12 internally developed and in-licensed medicines that are approved for use in China. With our first approval in the European Union in November 2021, BRUKINSA is now approved in the United States, China, the European Union and nine other countries and regions.

Read in the reply
General
SEC asked (3)
We note your response to our prior comment number 4, which states that you have not had material weather-related damages to your property or operations or any material impacts on the cost or availability of insurance. Provide us with an analysis supporting these statements, including quantitative information.
ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that it included new risk factor disclosure on page 92 of its most recent quarterly report on Form 10-Q, filed on November 4, 2021, which discusses the typhoon that hit the Company’s Guangzhou manufacturing facility in 2019. The typhoon did not cause material damage to the facility. However, the boundary area and the adjacent land were flooded, causing a power outage for a few days.
Rest of the answer

Afterwards, we built a gutter along the boundary and installed waterproof electricity cables to fortify the facility and to help prevent future interruptions. The installation fees were approximately $[****], which the Company does not consider material.

In addition, our risk factor disclosure states that we do not maintain any insurance other than property insurance for some of our buildings, vehicles and equipment. Accordingly, unexpected business interruptions resulting from disasters could disrupt our operations and thereby result in substantial costs and diversion of resources. Our production process requires a continuous supply of electricity. We have encountered power shortages historically in China due to restricted power supply to industrial users during summers when the usage of electricity is high and supply is limited or as a result of damage to the electricity supply network. Because the duration of those power shortages was brief, they had no material impact on our operations. Longer interruptions of electricity supply could result in lengthy production shutdowns, increased costs associated with restarting production and the loss of production in progress. Any major suspension or termination of electricity or other unexpected business interruptions could have a material adverse impact on our business, financial condition and results of operations.

In fiscal years 2019 and 2020, the cost of our property insurance was $[****] and $[****], respectively, which the Company does not consider material. To the extent these costs become material to an understanding of the Company’s business, results of operations and financial condition in the future, we will include such disclosure in our SEC filings.

Read in the reply
General
SEC asked (4)
We note your response to our prior comment number 5. Please tell us about the transition risks evaluated in preparing your response to prior comment number 5, including the items noted in our prior comment. Please also provide support for why you believe the effects of transition risks will not be material.
Rest of the question

Include information in your response explaining how your efforts to reduce the energy and carbon footprint of your operations address specific transition risks related to climate change that may affect you.

ONC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that, in preparing our response, we considered transition risks related to policy and regulatory changes that could impose operational and compliance burdens, market trends that may alter business opportunities, credit risks, or technological changes that may affect our business as a result of climate change.
Rest of the answer

Given the nature of our operations as a as a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, we do not believe that these risks are material to our business, results of operations or financial condition.

Nonetheless, as part of our continuing ESG efforts, in 2022, we plan to engage a third-party consultant to help us conduct a climate-specific risk assessment, following the TCFD framework. Annual disclosure of our Scope 1 and Scope 2 GHG emissions, as well as data and performance details, can be found in our annual ESG Report. For example, the environmental data on page 34 of our 2020 ESG Report covers the major operations of BeiGene, including our Beijing and Shanghai R&D centers, Suzhou and Guangzhou manufacturing facilities, all office buildings located in China, and the Cambridge office in the United States for the period from January 1, 2020 to December 31, 2020. Our Shanghai R&D center was put into service on November 20, 2020, so its data only covers the period from November to December 2020. We expect to report Scope 1 and 2 greenhouse gas emissions as well as water consumption, waste and packaging use for all of our facilities in our 2021 ESG Report that will be published in 2022.

Based on the assessment of our environmental performance, we have already begun efforts to reduce energy used in our operations. As we scale our production capacity, we understand the importance of designing our facilities and manufacturing processes to be as efficient as possible. In our manufacturing facilities in Suzhou and Guangzhou, we utilize a comprehensive environmental management system aligned with ISO 14001 standards.

Further, as our company grows, we are investing in new manufacturing facilities to meet anticipated demand. In 2020, energy use, greenhouse gas emissions, water consumption, and waste increased due to the construction of our Guangzhou plant. Across our manufacturing footprint, we have undertaken a number of upgrades to improve efficiency. For example, in 2019 at our Suzhou plant we introduced:

•A centrifugal variable frequency chiller that automatically adjusts load to meet operational requirements, resulting in a roughly 10% energy savings;

•An upgraded condensate water cooling control system, saving around 3,500 tonnes of water per year; and

•The reuse of purified run-off drainage as cooling water in lieu of municipal water for the cooling condensate system, saving about 17,000 tonnes of water per year.

In 2020, we upgraded to a more efficient steam trap, saving about 800 tonnes of steam per year and re-classified wasted print packing material to non-hazardous waste. In the Guangzhou plant, we cut the production time of a batch of biologics from seven to four days while doubling yields from each batch. In addition to increasing production capacity, these changes are estimated to have reduced water use and waste generation by more than 50% annually. We are also building a high-density warehouse with two-and-a half times the storage capacity of our previous warehouse, reducing electricity costs for temperature control by about 55%.

To the extent that there may be transition risks related to policy and regulatory changes that could impose operational and compliance burdens, technological changes, and transition to lower emissions technology on our Company, we believe our efforts to reduce the energy and carbon footprint of our operations will help us to address such risks. As discussed in our response letter dated October 29, 2021, none of our efforts to improve the energy and carbon footprint of our operations have materially impacted the Company’s business, financial condition, or results of operations.

In order to continue to monitor transition risks related to climate change, we plan to engage a third-party consultant to help us conduct a climate-specific risk assessment, following the TCFD framework. We will provide the result of our scenario analysis in future annual ESG Reports. To the extent any of the scenarios present transition risks that are material to an understanding of the Company’s business, results of operations or financial condition, we will include relevant disclosure in our future SEC filings.

***

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact the undersigned ([email protected] or 857-327-8286).

Read in the reply

Also in this review: request for more time, Sep 30, 2021, request for more time, Nov 24, 2021, closing letter, 2022-01-28

Form 10-K for the Fiscal Year Ended December 31, 2020

2021-03-23 to 2021-04-19 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2021-04-19
RevenueResults discussion (MD&A)Inventory
Results of Operations · Cost of Sales, page 121
SEC asked
You state on page 117 that costs to manufacture inventory in preparation for commercial launch of a product incurred prior to regulatory approval are expensed to research and development expense as incurred. You also state that cost of sales for newly launched products will not be recorded until the initial pre-launch inventory is depleted and additional inventory is manufactured.
Rest of the question

We note that your product revenue increased 39% in 2020 compared to 2019 which appears to relate to newly launched products offset by the decline in ABRAXANE sales. However, you disclose on page 121 that cost of sales decreased to $70.7 million in 2020 from $71.2 million in 2019. Please consider enhancing your disclosure of the reasons for the decrease in cost of sales despite the increase in product revenues. As it appears your cost of product revenues was only 23% of net product revenues in 2020 compared to 32% of net product revenue in 2019, please tell us the following: • the amount of estimated revenues represented by inventory on hand at December 31, 2020 for which manufacturing costs were expensed in prior periods as research and development expenses (i.e. "zero cost inventories"), • when you expect to finish selling the zero cost inventories, • the extent to which inventory capitalized may be required to be classified as noncurrent, • the shelf life of inventory that should be classified as non-current, and • what you estimate your gross margin percentage will be after the zero cost inventories are sold.

ONC answered
The Company began generating product revenue in September 2017 through its in-license agreement with Celgene Logistics Sàrl, now a wholly-owned subsidiary of Bristol Myers Squibb (BMS), to distribute the approved cancer therapies REVLIMID®, VIDAZA®, and ABRAXANE® in China. Following approval from the FDA in November 2019, the Company launched its first internally developed medicine, BRUKINSA®, in the United States. The Company launched its second internally developed medicine, tislelizumab, in China in March 2020, and launched BRUKINSA® in China in June 2020.
Rest of the answer

In July 2020, the Company began selling XGEVA® in China under its in-license agreement with Amgen.

The in-licensed medicines from BMS were the sole source of product revenue for the year ended December 31, 2018 and were the primary source of product revenue for the year ended

December 31, 2019, with BRUKINSA® sales in the United States representing only 0.5% of total product sales. The following table summarizes the Company’s product revenue, cost of sales, and gross margin on product revenue for the years ended December 31, 2018, 2019 and 2020:

Year Ended December 31,

2020 2019 2018

(dollars in thousands)

BMS in-licensed products $ 95,117 $ 221,557 $ 130,885

Internally developed products 205,060 1,039 —

Amgen in-licensed products 8,496 — —

Other 201 — —

Total Product Revenue $ 308,874 $ 222,596 $ 130,885

Cost of sales - product 70,657 71,190 28,705

Gross Margin on Product Revenue 77 % 68 % 78 %

Product revenues from BMS in-licensed medicines decreased 57% in the year ended December 31, 2020, primarily due to the suspension of the importation, sales and use of ABRAXANE® supplied to the Company by BMS in China in March 2020, as well as increased competition from generic products for REVLIMID® and the loss of volume-based procurement (“VBP”) bidding for VIDAZA®. However, product revenues from the Company’s higher-margin internally developed medicines increased significantly in the year ended December 31, 2020, with the China launches of tislelizumab and BRUKINSA®, and the continued launch of BRUKINSA® in the United States. Previously expensed zero or low cost inventories had an immaterial impact on the gross margin percentage, resulting in a benefit to cost of sales of only $0.3 million in 2020, in comparison to total cost of sales of $70.7 million.

On page 121 of the 2020 Annual Report, the Company disclosed the reason for the decrease in cost of sales despite increased product sales as being “…primarily due to a change in sales mix from lower margin in-licensed products to higher margin internally-developed products.” The Company believes that this disclosure, along with its disclosures on the variables impacting its products, address the material drivers of product sales and gross margin percentage. In future filings, the Company will disclose the impact of zero or low cost inventories on its reported cost of sales and gross margin percentage, to the extent material.

•the amount of estimated revenues represented by inventory on hand at December 31, 2020 for which manufacturing costs were expensed in prior periods as research and development expenses (i.e. "zero cost inventories").

RESPONSE: The Company had “zero cost inventories” and “low cost inventories” that were included in inventory on hand at December 31, 2020 related to certain BRUKINSA® batches that were in varying stages of completion at the time of regulatory approval. The Company expensed $2.0 million in prior periods as research and development expense related to zero and low cost inventories on hand at December 31, 2020. Assuming the current selling price and gross-to-net revenue reserve remains constant, the Company’s estimated net revenues represented by zero and low cost inventory on hand at December 31, 2020 is [****], which is expected to be fully utilized during the year ending December 31, 2021. The Company has based this forward-looking statement of its utilization of zero and low cost inventory during the year ending December 31, 2021 on its current expectations of product launch timing and sales, both of which are difficult to predict and may change during the course of the year.

•when you expect to finish selling the zero cost inventories.

RESPONSE: Based on the current projections, the Company expects to finish selling the zero or low cost inventory discussed above during the year ending December 31, 2021.

•the extent to which inventory capitalized may be required to be classified as noncurrent.

RESPONSE: The Company evaluated its overall inventory balance, including raw materials, work in process and finished goods as of December 31, 2020, and identified approximately $8.1 million of finished goods inventory that is not expected to be consumed in the next 12 months. This finished goods inventory does not pertain to the zero or low cost inventory discussed above. The Company believes this amount is not material to the financial statements, as it represents approximately 0.2% of total current assets and $0.1% of total assets as of December 31, 2020. In future reporting periods and related filings, the Company will evaluate its overall inventory balance and, to the extent applicable and material, will classify a portion as noncurrent.

•the shelf life of inventory that should be classified as non-current.

RESPONSE: The non-current inventory from finished goods relates to products with a remaining shelf life ranging from 40 to 44 months as of December 31, 2020.

RESPONSE: In 2021, the Company plans to continue the ongoing launches of its internally developed medicines and expects to launch additional medicines, potentially from its internal portfolio as well as from in-licensed commercial stage assets. Furthermore, as previously announced, three of the Company’s medicines marketed in China were included the National Reimbursement Drug List, resulting in price reductions effective March 1, 2021. The Company’s commercial portfolio consists of internally developed as well as in-licensed medicines that have a wide range of gross margins; therefore the product mix, product launch timing, pricing, and the sales of each individual medicine will have a significant impact on the overall gross margin. The consumption of zero cost and low cost inventories on hand is expected to have a small impact on gross margin. As noted above, the benefit in 2020 to gross margin as a result of zero or low cost inventories being expensed prior to sale was only $0.3 million, which would not have changed the Company’s reported gross margin percentage of 77% in 2020. Similarly, for 2021, the Company does not believe that the estimated benefit of $2.0 million to gross margin related to zero or low cost inventories being expensed in prior periods will result in a material change to its estimated gross margin percentage, which is expected to be [****]. The Company has based this forward-looking statement of its estimated gross margin percentage for 2021 on its current expectations of product mix, pricing, product launch timing, and estimated costs of production, all of which are difficult to predict and may change during the course of the year.

***

Due to the commercially sensitive nature of information contained in this letter, this submission is accompanied by the Company’s request for confidential treatment for selected portions of this letter. The Company has filed a separate letter with the Office of Freedom of Information and Privacy Act Operations in connection with the confidential treatment request, pursuant to Rule 83 of the Commission’s Rules on Information and Requests, 17 C.F.R. §200.83. For the Staff’s reference, we have enclosed a copy of the Company’s letter to the Office of Freedom of Information and Privacy Act Operations as well as a copy of this correspondence, marked to show the portions redacted from the version filed via EDGAR and for which the Company is requesting confidential treatment.

If you or any other member of the Staff have any questions with regard to the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please contact the undersigned ([email protected] or 781-801-1888), or Scott A. Samuels, Senior Vice President, General Counsel of the Company (Scott. [email protected] or 857-327-8286).

Read in the reply
In its next report

First report after the company's reply of Apr 13, 2021: 10-Q filed May 6, 2021 ↗, against the 10-Q filed Nov 5, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2021-04-19

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 36 letters filed since 2021-03-23. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.